Company profile: Optinose
1.1 - Company Overview
Company description
- Provider of nasal drug delivery technologies and combination drug/device therapies based on Bi-Directional Delivery, including Exhalation Delivery Systems for efficient deep nasal delivery. Offerings include XHANCE nasal spray for nasal polyps, ONZETRA Xsail for migraine treatment, and liquid and powder delivery devices using exhaled breath.
Products and services
- Exhalation Delivery Systems: Custom-engineered technologies that use patent-protected Bi-Directional Delivery to efficiently propel therapeutics deep into the nasal cavity via patient exhalation for diverse ENT treatments
- XHANCE: Prescription-grade nasal spray that harnesses Exhalation Delivery System technology to deliver medication deeply into the nasal cavity for the treatment of nasal polyps
- ONZETRA Xsail: Powder-based device that delivers sumatriptan powder via the nasal cavity to treat migraines using OptiNose’s nasal delivery approach
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Optinose
Mipharm
HQ: Italy
Website
- Description: Provider of pharmaceutical manufacturing across oral solids, oral liquids, nasal sprays, semi-solids, and suppositories; customized and secure packaging; research and development for new formulations and optimization of existing ones; clinical trial logistics; and formulation development and production of experimental drugs for clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mipharm company profile →
Flat Medical
HQ: United States
Website
- Description: Provider of safety technology solutions for clinical procedures, including EpiFaith Syringe, an epidural space locating syringe that provides real-time, objective pressure information with a visual signal to ensure safer procedures, and EpiFaith CV, a syringe for central venous catheterization featuring auto-aspiration and pressure-detecting mechanisms to improve needle control and reduce the risk of arterial puncture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flat Medical company profile →
NTT
HQ: United States
Website
- Description: Provider of practical drug delivery systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NTT company profile →
Xanadu Bio
HQ: United States
Website
- Description: Provider of nanoparticle delivery technology for mRNA and other nucleic acids, using PACE platform technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xanadu Bio company profile →
Credence MedSystems
HQ: United States
Website
- Description: Provider of drug delivery and specialty pharmaceutical solutions focused on safe medication administration, offering syringe systems including the Companion Safety Syringe with end-of-dose cues, passive needlestick safety, reuse prevention and pre-attached needle; Dual Chamber Reconstitution Syringe; Credence Connect for real-time injection monitoring; Micro-Dose Syringe for ocular use; and Multi-Site Syringe.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Credence MedSystems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Optinose
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Optinose
2.2 - Growth funds investing in similar companies to Optinose
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Optinose
4.2 - Public trading comparable groups for Optinose
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →